Bariatric surgery is generally safe, but problems after the procedure can occur. It is not clear if patients with hypothyroidism have higher chances of complications after bariatric surgery. This study was done to find out the risks of bariatric surgery in patients with hypothyroidism.
Background: Heterozygosity of genetically encoded misfolded mutant thyroglobulin (TG, the thyroid hormone protein precursor) occurs with a frequency estimated at 1-in-217 people worldwide, resulting in subclinical hypothyroidism that largely escapes medical detection. However, patients carrying biallelic TG mutation, when untreated, are frankly hypothyroid unless and until they develop a massive goiter. To date, TG is the only proven endogenous precursor protein for thyroid hormone synthesis in vertebrates.
A significant change in the 2025 thyroid cancer guidelines is an increase in the recommendation of lobectomy. Prior guidelines indicate that completion thyroidectomy is considered in up to 20% of patients with a lobectomy and cancer >2 and ≤4 cm. This paper summarizes the changes in recommendations for completion thyroidectomy in the 2025 ATA differentiated thyroid cancer guidelines.
Who is eligible for TAE and who is not? How does it compare with surgery, radioactive iodine, or thermal ablation? What should we be telling our patients about expectations, safety, and follow-up after TAE procedures?
All Thyroid® articles are free to read through the end of March as we transition to the new Sage Journals.
This podcast was created in partnership with the American Thyroid Association to discuss up-to-date diagnosis and management of a wide array of thyroid diseases.
The study authors reviewed the medical records for all patients who underwent partial thyroidectomy at their institution between 2013 and 2020. They identified 425 patients who met study criteria. The authors then identified which of these patients were prescribed levothyroxine after surgery.
Professional medical societies frequently use surveys to improve their decision making. When a survey impacts more than one society, cooperation between societies might facil- itate identification of common or disparate priorities, needs, and perceptions, as well as implementation of identified action items.
This document aims to provide a state-of-the-art status report on the progress achieved in thyroid testing, including thyrotropin (TSH), thyroxine (T4), and triiodothyronine (T3). The target audience for this document includes general practitioners, endocrinologists, and laboratory professionals.
Thyrotropin (TSH) and free thyroxine (fT4) are the two hormones initially measured in blood to assess hypoand hyperthyroidism and to guide treatment decisions.1–3 Some guidelines and recommendations suggest specific concentrations for these hormones to guide decision making.4 Therefore, accurate and reliable TSH and fT4 tests are needed to ensure correct patient care, making the standardization of thyroid function tests to assess both thyroid gland function and therapeutic drug monitoring a priority.
AMERICAN THYROID ASSOCIATION® , ATA® , THYROID® , CLINICAL THYROIDOLOGY® , and the distinctive circular logo are registered in the U.S. Patent and Trademark Office as trademarks of the American Thyroid Association® , Inc.© 2026 American Thyroid Association.
